Imaging-Guided Interventional Cancer Combination Immunotherapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 55
Special Issue Editor
2. Department of Biomedical Engineering, University of California, Irvine, CA, USA
3. Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA
4. Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, USA
Interests: cell/molecular biology; cancer immunology; magnetic resonance imaging; immunotherapy; imaging biomarkers; combination therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The development of novel treatment approaches will further advance our knowledge and support our fight to cure cancer. With state-of-the-art equipment for cancer research, our research group has focused on novel image-guided cancer immunotherapy including immune checkpoint inhibitors, natural killer and dendritic cell-based immunotherapy, image-guided small molecular inhibitor and antibody immunotherapy, image-guided combination therapies of local ablation and targeted immunotherapy, image-guided drug delivery for cancer and utilization of artificial intelligence for the prediction of prognosis and evaluation of clinical outcomes. Our research team investigates rabbit, mouse and rat tumor models to optimize and develop MRI sequences for the assessment of therapeutic responses.
Prof. Dr. Zhuoli Zhang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- image-guided cancer immunotherapy
- image-guided combination therapies
- local ablation
- targeted immunotherapy
- the assessment of therapeutic response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
